OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up
Yaël C. Cohen(Sheba Medical Center), María-Victoria Mateos Manteca, Enrique M. Ocio(Universidad de Salamanca), Michael Chu(University of Michigan), Brandi Hilder(Sheba Medical Center), Michelle Peterson(Janssen (United States)), Hila Magen(Sheba Medical Center), Jill Vanak(Sheba Medical Center), Albert Oriol(Institut Català d'Oncologia), Arnob Banerjee(Johnson & Johnson (United States)), Michaël Sébag(Sheba Medical Center), Irit Avivi(Tel Aviv Sourasky Medical Center), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Maria Krevvata(Janssen (United States)), Kihyun Kım(State University of New York), Daniel Morillo(Sheba Medical Center), Sung‐Soo Yoon(Seoul National University Hospital), Chang‐Ki Min(The Catholic University of Korea Seoul St. Mary's Hospital), Moshe E. Gatt(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Natalia Quijano Cardé, Emma Scott(Johnson & Johnson (United States))
Cited by 0
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA–PEG block copolymers
|Journal of Controlled Release|2003|793
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719